The antitrust case against Live Nation Entertainment is entering a pivotal new phase, with federal prosecutors, a coalition of state attorneys general, and the company now locked in a consequential dispute over how—and when—the court should determine potential remedies.
In a joint letter (read it here) filed Friday in federal court in New York, the parties outlined sharply conflicting visions for what happens next after trial. At the center of the fight is a deceptively simple question with major implications: should the court evaluate the state’s proposal to breakup Live Nation and Ticketmaster at the same time it reviews the federal government’s proposed settlement with Live Nation struck just one week into the trial?
To understand why the dispute matters, it helps to start with the framework governing the federal settlement. Under the Tunney Act, formally known as the Antitrust Procedures and Penalties Act, the U.S. Department of Justice must submit any antitrust settlement to a federal judge for approval.
That process requires the government to publicly file the proposed agreement, open a 60-day window for public comment, and then respond to those comments before a judge determines whether the deal is in the “public interest.” While that review provides transparency and oversight, it is intentionally limited. Courts generally defer to the DOJ’s judgment and do not attempt to craft their own remedies, focusing instead on whether the settlement reasonably addresses the alleged harm.
That limited scope is precisely why the timing of the remedies phase has become so contentious. The states are seeking changes at Live Nation that could go beyond the DOJ’s settlement, potentially including breaking up the company. If the Tunney Act process is completed first, the federal settlement could effectively establish a baseline that defines Live Nation’s obligations, making it harder for the states to argue for more expansive measures later.
The states are therefore pushing for both tracks—the Tunney Act review and their own remedies case—to proceed in parallel. Their position is that the court should consider all potential remedies at once, rather than in sequence, so it can evaluate how they interact and avoid issuing inconsistent or duplicative orders. They also argue that running the processes together would speed up the path to meaningful relief and prevent delays that could extend well beyond the conclusion of the Tunney Act review. According to their filing, postponing remedies litigation until after the federal settlement is finalized could delay relief by nearly a year.
Live Nation sees it differently. The company is urging the court to take a step-by-step approach, first resolving its post-trial motions involving a controversial expert witness, and then complete the Tunney Act process before turning to any additional remedies sought by the states. From Live Nation’s perspective, the DOJ’s settlement will define the competitive landscape going forward, and only after that baseline is established can the court properly assess whether further intervention is necessary. Proceeding in parallel, the company argues, would force the court to evaluate the states’ proposals “in a vacuum,” without knowing what obligations are already in place, increasing the risk of conflicting or redundant requirements.
The dispute is not just about efficiency; it also carries strategic implications. Live Nation has warned that arguments it makes defending the adequacy of the DOJ settlement during the Tunney Act process could be used against it in the states’ separate case if both proceed at the same time.
Overlaying all of this is Live Nation’s plan to challenge the trial outcome itself through post-trial motions under Federal Rules of Civil Procedure 50 and 59. A Rule 50 motion allows the company to argue that the evidence presented at trial was legally insufficient to support a verdict against it, meaning no reasonable factfinder could have reached that conclusion. If successful, such a motion could overturn the verdict entirely without the need for further proceedings. A Rule 59 motion, by contrast, seeks a new trial or modification of the judgment based on alleged legal errors, improper admission of evidence, or other issues that may have affected the fairness of the trial.
These motions are a critical inflection point. If Live Nation succeeds on either front, the scope of the case—and any potential remedies—could change dramatically or disappear altogether. That uncertainty is a key reason the company argues it would be premature to launch full-scale remedies litigation before those issues are resolved.
Another point of contention involves the testimony of economist Dr. Rosa Abrantes-Metz, a key expert for the plaintiffs. Live Nation has moved to strike her testimony, likely challenging its reliability or relevance under the standards governing expert evidence. The states are seeking permission to file an additional brief defending her work as part of their response to the post-trial motions, arguing that the court previously indicated they would have a full opportunity to address the issue. Live Nation opposes further briefing, maintaining that the matter has already been fully argued and does not warrant additional submissions.
The outcome of that dispute could carry significant weight. Expert economic testimony often forms the backbone of antitrust cases, helping to establish market power, competitive harm, and the need for remedies. If Abrantes-Metz’s testimony were excluded, it could weaken key elements of the plaintiffs’ case heading into the remedies phase.
For the states, the push to move quickly is about more than procedural preference. They argue that delaying remedies would prolong the competitive conditions they are challenging and reduce the practical impact of any eventual relief. Just as importantly, they want to ensure their proposals are considered on equal footing with the federal settlement, rather than being constrained by it after the fact.
Judge Arun Subramanian now faces the task of deciding how to sequence the next phase of the case—a decision that will influence both the timing and the substance of any final outcome. If the court adopts Live Nation’s approach, the DOJ settlement could be finalized first, establishing the framework for any additional remedies. If the states prevail, the case could move forward on parallel tracks, with the court weighing multiple layers of potential relief at once.
Either way, the focus of the litigation has shifted. The central question is no longer just whether Live Nation violated antitrust law, but how far regulators can go in reshaping the company’s business—and how quickly those changes can take effect.
